[{"orgOrder":0,"company":"Adagene Suzhou Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Adagene Suzhou Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Adagene Suzhou Limited \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Adagene Suzhou Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Megestrol Acetate","moa":"Progesterone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Wigen Biomedicine Technology","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"WJ1075","moa":"XPO1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Wigen Biomedicine Technology","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Oral","sponsorNew":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Wigen Biomedicine Technology \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Antengene","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ WuXi Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Antengene \/ WuXi Biologics"},{"orgOrder":0,"company":"Chengdu Baiyu Pharmaceutical","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Chengdu Baiyu Pharmaceutical","amount2":1.1699999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":1.1699999999999999,"dosageForm":"Oral","sponsorNew":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Baiyu Pharmaceutical \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Hillhouse Capital Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0.41999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.41999999999999998,"dosageForm":"Oral","sponsorNew":"I-Mab Biopharma \/ Hillhouse Capital Group","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Hillhouse Capital Group"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asymchem Laboratories \/ LaNova Medicines","highestDevelopmentStatusID":"1","companyTruncated":"Asymchem Laboratories \/ LaNova Medicines"},{"orgOrder":0,"company":"Stemirna Therapeutics","sponsor":"Peking University Cancer Hospital & Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Neoantigen mRNA Personalised Cancer Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Stemirna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute","highestDevelopmentStatusID":"1","companyTruncated":"Stemirna Therapeutics \/ Peking University Cancer Hospital & Institute"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TJ004309","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Undisclosed","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"I-Mab Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"I-Mab Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Junshi Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Toripalimab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Shanghai Junshi Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Junshi Biosciences \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Junshi Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Xuanzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"KM257","moa":"HER2D4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Xuanzhu Biopharmaceutical"},{"orgOrder":0,"company":"EdiGene","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ET-02","moa":"CD19","graph1":"Oncology","graph2":"Undisclosed","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology","highestDevelopmentStatusID":"1","companyTruncated":"EdiGene \/ The First Affiliated Hospital of Henan University of Science and Technology"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GC027","moa":"T-cell receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gracell Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Gracell Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CSPC Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Undisclosed","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qilu Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-00420","moa":"AURKA","graph1":"Oncology","graph2":"Undisclosed","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hubei Soundny Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hubei Soundny Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hubei Soundny Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Hubei Soundny Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"FCN-338","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Fosun Pharmaceutical","amount2":0.44,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.44,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"Fosun Pharmaceutical \/ Eli Lilly"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLL1\/CD33 CAR-T Cell","moa":"CLL1\/CD33","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"Guangzhou Bio-gene Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BCMA\/GPRC5D Double CAR-T Cell","moa":"B-cell maturation antigen\/GPRC5D","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangzhou Bio-gene Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Guangzhou Bio-gene Technology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Guangzhou Bio-gene Technology \/ Inapplicable"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT307","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"GRIT Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GT201","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"GRIT Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GRIT Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GRIT Biotechnology \/ Inapplicable"}]
Find Novel Oncology Drugs in Clinical Development in CHINA
Sponsor :
The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital
Sponsor :
The First Hospital of Jilin University | The First Affiliated Hospital of Bengbu Medical University | Chongqing Traditional Chinese Medicine Hospital | The First Affiliated Hospital of Henan University of Science and Technology | Qianfoshan Hospital
Details :
Ascentage and Takeda entered into an agreement that granted Takeda an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib) for Chronic Myeloid Leukemia.
Reset All
